We are live on ! Find out more
ABUS icon

Arbutus Biopharma
ABUS

80 hedge funds and large institutions have $79.4M invested in Arbutus Biopharma in 2020 Q4 according to their latest regulatory filings, with 28 funds opening new positions, 22 increasing their positions, 12 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

133% more first-time investments, than exits

New positions opened: 28 | Existing positions closed: 12

83% more repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 12

23% more funds holding

Funds holding: 65 → 80 (+15)

5% more capital invested

Capital invested by funds: $75.5M → $79.4M (+$3.9M)

2.87% less ownership

Funds ownership: 29.12% → 26.25% (-2.9%)

32% less call options, than puts

Call options by funds: $4.67M | Put options by funds: $6.87M

Holders
80
Holders Change
+15
Holders Change %
+23.08%
% of All Funds
1.42%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
28
Increased
22
Reduced
12
Closed
12
Calls
$4.67M
Puts
$6.87M
Net Calls
-$2.2M
Net Calls Change
-$1.83M

Top Buyers

1
BlackRock
BlackRock
New York
+$2.72M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$1.77M
3
Renaissance Technologies
Renaissance Technologies
New York
+$1.53M
4
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT)
United Kingdom
+$1.2M
5
Group One Trading
Group One Trading
Illinois
+$893K

Top Sellers

1
FCMI
Foresite Capital Management IV
California
-$10.4M
2
Morgan Stanley
Morgan Stanley
New York
-$5.21M
3
Goldman Sachs
Goldman Sachs
New York
-$682K
4
Deutsche Bank
Deutsche Bank
Germany
-$400K
5
Assenagon Asset Management
Assenagon Asset Management
Luxembourg
-$139K
Name Holding Trade Value Shares
Change 		Change in
Stake
ProShare Advisors
51
ProShare Advisors
Maryland
$47K +$45.9K +13,104 New
SC
52
Scotia Capital
Ontario, Canada
$42K +$35 +10 +0.1%
LPL Financial
53
LPL Financial
California
$38K +$37.1K +10,600 New
IWM
54
IHT Wealth Management
Illinois
$36K – – –
SAM
55
Secure Asset Management
Michigan
$36K – – –
SPIA
56
Steward Partners Investment Advisory
New York
$25K +$24.5K +7,000 New
Bank Julius Baer & Co
57
Bank Julius Baer & Co
Switzerland
$23K +$17.4K +4,979 +332%
CG
58
Cutler Group
California
$18K – – –
Bank of America
59
Bank of America
North Carolina
$18K +$7.12K +2,033 +68%
Wells Fargo
60
Wells Fargo
California
$17K -$2.19K -624 -12%
TRCT
61
Tower Research Capital (TRC)
New York
$16K +$613 +175 +4%
SIAP
62
Sterling Investment Advisors (Pennsylvania)
Pennsylvania
$14K – – –
PGAM
63
Princeton Global Asset Management
New Jersey
$7K +$7K +2,000 New
PCM
64
Penserra Capital Management
California
$6K +$6.83K +1,950 New
JWA
65
JFS Wealth Advisors
Pennsylvania
$4K +$3.5K +1,000 New
LFG
66
Larson Financial Group
Missouri
$3K +$3.15K +901 New
SFS
67
Sowell Financial Services
Arkansas
$3K +$3.24K +925 New
GWM
68
Geneos Wealth Management
Colorado
$3K +$3.5K +1,000 New
FDCDDQ
69
Federation des caisses Desjardins du Quebec
Quebec, Canada
$2.84K – – –
HIA
70
Harbor Investment Advisory
Maryland
$2K – – –
PA
71
Parallel Advisors
California
$2K – – –
AF
72
Advisornet Financial
Minnesota
$1K – – –
NFG
73
Next Financial Group
Texas
$1K – – –
RG
74
Retirement Group
California
$1K – – –
TF
75
TimeScale Financial
Massachusetts
$1K – – –
1 2
3
4

ABUS Hedge Fund Activity: Q4 2020 in Review

80 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Arbutus Biopharma (ABUS) for Q4 2020, worth a combined $79.4M — up 5.2% from $75.5M a quarter earlier.

Buyers outnumbered sellers: 28 funds opened new ABUS positions and 12 closed out — a net gain of 16 holders — while 22 added to existing stakes and 12 trimmed.

The largest buyer was BlackRock, adding an estimated $2.72M. The largest seller was Foresite Capital Management IV, exiting entirely with an estimated $10.4M sold.

  • 80 institutional investors held Arbutus Biopharma (ABUS) as of Q4 2020, up from 65 in Q3 2020.
  • Funds reported $79.4M of Arbutus Biopharma stock for Q4 2020, up 5.2% quarter-over-quarter.
  • 28 funds opened new Arbutus Biopharma positions in Q4 2020 and 12 closed out, a net change of +16 holders.
  • The largest Arbutus Biopharma buyer in Q4 2020 was BlackRock, an estimated $2.72M added.
  • The largest Arbutus Biopharma seller in Q4 2020 was Foresite Capital Management IV, an estimated $10.4M sold.

Based on aggregated 13F filings for Q4 2020.